Brokers Offer Predictions for GPCR FY2024 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - HC Wainwright issued their FY2024 earnings per share estimates for shares of Structure Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.77) per share for the year. HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Structure Therapeutics' Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at ($1.81) EPS.

A number of other equities analysts have also recently weighed in on GPCR. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an "overweight" rating and a $118.00 target price on the stock. Finally, JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a report on Friday, August 9th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $85.67.

Structure Therapeutics Stock Up 6.8 %

Shares of GPCR stock traded up $2.11 during trading hours on Friday, hitting $33.35. 826,642 shares of the company's stock were exchanged, compared to its average volume of 785,200. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $62.85. The firm has a market cap of $1.91 billion, a P/E ratio of -44.50 and a beta of -3.41. The firm has a 50 day moving average of $37.46 and a two-hundred day moving average of $39.32.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company's stock valued at $341,015,000 after acquiring an additional 221,851 shares during the last quarter. FMR LLC increased its stake in Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company's stock worth $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock valued at $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in shares of Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company's stock valued at $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company's stock worth $94,531,000 after purchasing an additional 150,000 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.